Brightsurf Science News & Current Events

October 21, 2018
A dog's color could impact longevity, increase health issues
New research led by the University of Sydney has revealed the life expectancy of chocolate Labradors is significantly lower than their black and yellow counterparts.

Labrador retrievers at risk of various health problems
Labrador retrievers, the second most popular dog breed in the UK, are vulnerable to a number of health conditions, according to a study published in the open-access journal Canine Genetics and Epidemiology.

Understanding the building blocks for an electronic brain
Computer bits are binary, with a value of 0 or one.

Cannabis improves symptoms of Crohn's disease despite having no effect on gut inflammation
In a randomized, placebo-controlled study, researchers from Israel have shown that cannabis can produce clinical remission in up to 65 percent of individuals after eight weeks of treatment, but that this improvement does not appear to result from a dampening down of the underlying inflammatory process.

Erlotinib improves progression-free survival in early mutated non-small cell lung cancer
Neoadjuvant erlotinib benefits selected epidermal growth factor receptor (EGFR)-mutated patients who undergo complete resection of stage IIIA-N2 stage non-small cell lung cancer (NSCLC), shows a randomised study comparing erlotinib with gemcitabine plus cisplatin as neoadjuvant treatment, presented at the ESMO 2018 Congress in Munich.

PROs indicate brachytherapy alone is the superior treatment
Patient-Reported Outcomes (PROs) from the NRG Oncology trial RTOG 0232 comparing a combined treatment of external beam therapy and brachytherapy (EBT+B) to transperineal interstitial permanent brachytherapy (B) alone indicate a significantly different clinician and patient-reported late toxicity profile between arms despite similarities in progression-free survival results.

Avelumab plus axitinib significantly improve PFS in untreated renal cell carcinoma
A combination of the immune checkpoint blocker, avelumab, plus the tyrosine kinase inhibitor (TKI), axitinib, significantly improves progression-free survival (PFS) in previously untreated patients with advanced renal cell carcinoma (RCC) in a phase 3 study, according to results presented at ESMO 2018 Congress.

Interaction of pretreatment immune inflammatory state of patient outcomes following RT
Data from a validation study of NRG-RTOG 0521 suggests that, while there is no association between an elevated level of C-reactive protein (CRP) and disease-free survival (DFS); higher levels of pretreatment interleukin 10 (IL-10) were linked to lower rates of DFS.

Local radiotherapy improves survival in metastatic prostate cancer with low disease burden
Radiotherapy to the prostate improves overall survival in men newly diagnosed with metastatic prostate cancer who have a low metastatic disease burden but not in those with higher burden of disease, according to results from a pre-planned analysis of a large comparison study reported at ESMO 2018.

Radiation therapy cuts low risk of recurrence in half for patients with good risk breast cancer
A subset of patients with low-risk breast cancer is highly unlikely to see cancer return following breast conservation surgery but can lower that risk even further with radiation therapy, finds a new long-term clinical trial report.

Olaparib maintenance extends PFS by estimated 3 years in advanced ovarian cancer
Two-year maintenance therapy with olaparib, a PARP (poly ADP ribose polymerase) inhibitor, olaparib, led to a substantial, unprecedented improvement in progression-free survival (PFS) in newly diagnosed patients with advanced ovarian cancer and a BRCA1 or 2 mutation, results from the phase 3 SOLO-1 trial show.
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.